에 대한 최신 뉴스 Johnson & Johnson (NYSE:JNJ) 주식

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Biotech

Large Cap

News

Health Care

General

화요일 존슨앤드존슨(NYSE:JNJ)은 선불금 6억 달러로 V-웨이브(V-Wave)를 인수하기로 합의했으며, 추가 규제 및 상업적 마일스톤 지불 가능성은 최대 약 11억 달러에 이른다.

존슨앤드존슨은 심부전 혁신업체 V-웨이브를 인수하기 위해 17억 달러 거래 체결

Earnings

Equities

Pre-Market Outlook

Markets

Trading Ideas

ASML

SAVE

수요일 오전 (동부 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 월스트리트는 존슨앤드존슨(NYSE:JNJ)이 개장 전에 분기 이익을 주당 2.70달러, 매출 223억 1천만 달러로 발표할 것으로 예상하고 있다. 벤징가 프로의 데이터에 의하면, 존슨앤드존슨의 주식은 시간외 거래에서 0.5% 상승한 151.80달러를 기록했다.

수요일 주목해야 할 주식: ASML, 유나이티드 항공 그리고 3종목

AMZN

SPDR Dow Jones Industrial Average ETF Trust

GOOG

GOOGL

INTC

MAGS

MSFT

NVDA

TSLA

S&amp;P 500과 같은 광범위한 주식 시장 지수는 2024년 상반기에 사상 최고치를 기록했다. 다우존스 산업평균지수도 사상 최고치를 경신했지만, 올해 상반기에는 수익률이 더 낮았다. 다우존스 산업평균지수에서 가장 큰 상승세를 보인 종목과 부진 종목을 살펴보겠다.

2024년 상반기 다우존스 산업평균지수의 가장 큰 상승주 5종목, 하락주 5종목

JOHNSON & JOHNSON ORD

Dean Omar Branham Shirley represents family of deceased woman
A Circuit Court in Cook County, Ill., has denied a request by Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) for a new trial in a mesothelioma lawsuit decided in April, upholding a jury verdict and award of $45 million in the asbestos-related death of a mother of six.
Johnson &amp; Johnson raised multiple issues in its motion for a new trial, but in each case, the court either found for the plaintiff or determined that any issue did not substantially prejudice the jury.
The decision from Judge Patrick J. Sherlock means the jury's verdict in the case filed by the children of Theresa Garcia will stand.

Legal

A Circuit Court In Cook County, Illinois Has Denied A Request By Johnson & Johnson For A New Trial In A Mesothelioma Lawsuit Decided In April; Upholding A Jury Verdict And Award Of $45M

On Friday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-65.
The <a target="_blank" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-to-discontinue-phase-2-field-study-evaluating-investigational-antiviral-for-the-prevention-of-dengue" rel="noreferrer noopener">decision</a> to discontinue this study is part of a strategic reprioritization of the company&#8217;s Communicable Diseases research and development (R&amp;D) portfolio. No safety issues were identified.
Efficacy data from the Phase 2 field study will be available once the final data analyses, which are now underway, are complete.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41143856/johnson-johnsons-erleada-shows-improved-overall-survival-in-prostate-cancer-patients-compared-to-" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer&#8217;s Drug</a>.
Mosnodenvir (formerly JNJ-1802) was shown to be safe and well tolerated in previous Phase 1 and Phase 2a clinical studies.
In October 2023, results from the Phase 2a human challenge study found that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo.
The study <a target="_blank" href="https://www.jnj.com/media-center/press-releases/janssen-announces-promising-antiviral-activity-against-dengue-in-a-phase-2a-human-challenge-model" rel="noreferrer noopener">evaluated</a> different dosing regimens – low, medium or high – of JNJ-1802 against an attenuated dengue 3 serotype (DENV-3) in healthy adults.
All participants received daily doses of JNJ-1802 or a placebo over 26 days, during which they were challenged with DENV-3 on day 5.
All participants were monitored over 85 days. The study found a dose-dependent antiviral effect on the detectability of DENV-3 RNA and time to first onset of detectable DENV-3 RNA compared to placebo and was safe and well-tolerated.
In May, Takeda Pharmaceutical Co Ltd&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) dengue vaccine&nbsp;received World Health Organization&#8217;s (WHO) prequalification.&nbsp;
TAK-003 is the second dengue vaccine to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/04/31935884/united-nations-specialized-agency-in-preliminary-talks-with-takeda-for-dengue-vaccine-currently-u" rel="noreferrer noopener">be prequalified by WHO</a>.&nbsp;
WHO recommended using TAK-003 in children aged 6–16 in settings with high dengue burden <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38853309/takedas-dengue-vaccine-gets-who-approval-eligible-for-un-procurement" rel="noreferrer noopener">and transmission intensity</a>.&nbsp;
Price Action: JNJ stock is down 0.60% at $159.53 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41187920/lucid-air-electric-vehicles-join-blink-chargings-envoy-program-details" target="_blank" rel="noreferrer noopener">Lucid Air Electric Vehicles Join Blink Charging&#8217;s Envoy Program: Details</a>.</li>
</ul>
Photo via Shutterstock

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization

Johnson & Johnson To Discontinue Phase 2 Field Study Evaluating Investigational Antiviral For Prevention Of Dengue; Decision To Discontinue Study Part Of A Strategic Reprioritization Of Company's Communicable Diseases R&D Portfolio; No Safety Issues Identified To Date In Phase 2 Field Study

Financial giants have made a conspicuous bearish move on Johnson &amp; Johnson. Our analysis of options history for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) revealed 8 unusual trades.
Delving into the details, we found 25% of traders were bullish, while 75% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $294,749, and 4 were calls, valued at $638,264.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $155.0 and $162.5 for Johnson &amp; Johnson, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Johnson &amp; Johnson options trades today is 2676.43 with a total volume of 5,256.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Johnson &amp; Johnson's big money trades within a strike price range of $155.0 to $162.5 over the last 30 days.
<h3>Johnson &amp; Johnson Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727889417_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$2.61</td>
<td>$2.5</td>
<td>$2.52</td>
<td>$162.50</td>
<td>$504.0K</td>
<td>761</td>
<td>2.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$1.23</td>
<td>$1.22</td>
<td>$1.23</td>
<td>$160.00</td>
<td>$128.4K</td>
<td>1.0K</td>
<td>380</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$1.29</td>
<td>$1.28</td>
<td>$1.28</td>
<td>$160.00</td>
<td>$103.8K</td>
<td>1.0K</td>
<td>2.2K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/25/24</td>
<td>$2.92</td>
<td>$2.91</td>
<td>$2.92</td>
<td>$162.50</td>
<td>$55.7K</td>
<td>30</td>
<td>345</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$11.0</td>
<td>$10.85</td>
<td>$10.85</td>
<td>$155.00</td>
<td>$45.5K</td>
<td>3.2K</td>
<td>95</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Having examined the options trading patterns of Johnson &amp; Johnson, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Johnson &amp; Johnson</h3>
<ul>
<li>Trading volume stands at 2,469,466, with JNJ's price down by -0.48%, positioned at $161.21.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 13 days.</li>
</ul>
<h3>What The Experts Say On Johnson &amp; Johnson</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $207.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $175. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $215. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $215. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $215. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $215.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Johnson &amp; Johnson options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Johnson & Johnson's Options: A Look at What the Big Money is Thinking

Wednesday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) revealed results from a head-to-head study of Erleada (apalutamide) compared to Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Xtandi (enzalutamide).
The data showed that Erleada (apalutamide) provided a statistically significant overall survival benefit at 24 months compared to enzalutamide in patients with metastatic castration-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41140779/erleada-apalutamide-demonstrates-statistically-significant-and-clinically-meaningful-improvement-i" rel="noreferrer noopener">sensitive prostate cancer (mCSPC)</a>.
Presented at the 6th European Congress of Oncology Pharmacy, the study of nearly 4,000 patients represents the largest real-world, head-to-head analysis of these two androgen receptor pathway inhibitors (ARPIs) in mCSPC.
The analysis demonstrated patients with mCSPC who initiated Erleada as their first ARPI had a statistically significant 23% reduction in their risk of death at 24 months compared to patients who initiated enzalutamide.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/41140319" rel="noreferrer noopener">Humana Faces Sharp Decline In Medicare Star Ratings For 2025, Braces For 2026 Revenue Hit</a>
The proportion of patients alive at 24 months (87.6%) observed in the Erleada cohort in this real-world analysis is consistent with that in the Phase 3 TITAN trial (82.4%).
TITAN demonstrated a statistically significant superior overall survival benefit of Erleada plus androgen deprivation therapy (ADT) compared to ADT alone at the primary analysis after a median of 22.7 months of follow-up and at the final analysis after a median of 44 months of follow-up.
On Tuesday, Johnson &amp; Johnson&nbsp;<a target="_blank" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-to-invest-more-than-2-billion-in-new-advanced-technology-manufacturing-facility-in-north-carolina-to-support-robust-portfolio-growth" rel="noreferrer noopener">announced</a> an investment of more than $2 billion to build a biologics manufacturing facility in Wilson, North Carolina.
The new facility will expand the production of the company&#8217;s portfolio and pipeline of biologics in support of&nbsp;its broader plan to advance more than 70 novel therapies and product expansion filings and launches by the end of the decade.
When fully operational, the site will employ approximately 420 full-time employees.
Construction is anticipated to begin in the first half of 2025.
Price Action: JNJ stock is down 0.26% at $161.58 at last check Wednesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41141541/whats-going-on-with-chinese-stocks-alibaba-nio-xpeng-li-auto-on-wednesday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Chinese Stocks Alibaba, NIO, XPeng, Li Auto On Wednesday?</a></li>
</ul>

Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug

Largest head-to-head real-world study in mCSPC demonstrated that ERLEADA&#xAE; reduced risk of death by 23 percent at 24 months compared to enzalutamide
LISBON, Portugal, Oct. 2, 2024 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA&#xAE; (apalutamide) provided a statistically significant overall survival benefit at 24 months compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC). Presented at the 6th European Congress of Oncology Pharmacy (ECOP) in Lisbon, Portugal, on October 2 (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4268936-1&amp;h=3004083318&amp;u=https%3A%2F%2Fecop.events%2Fwp-content%2Fuploads%2F2024%2F09%2FClinical_evaluation.pdf&amp;a=Abstract+%23P31">Abstract #P31</a>), this study of nearly 4,000 patients represents the largest real-world, head-to-head analysis of these two androgen receptor pathway inhibitors (ARPIs) in mCSPC.
The study applied U.S. Food and Drug Administration (FDA) real-world evidence guidance and employed robust methodology, data sources and a large, diverse cohort to ensure validity of its findings. The retrospective study identified mCSPC patients who initiated ERLEADA&#xAE; or enzalutamide between December 16, 2018 – December 31, 2023, based on patient data in electronic databases. There were 1,800 ERLEADA&#xAE; and 1,909 enzalutamide initiators who met study criteria.
The analysis demonstrated patients with mCSPC who initiated ERLEADA&#xAE; as their first ARPI had a statistically significant 23 percent reduction in their risk of death at 24 months compared to patients who initiated on enzalutamide (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.62-0.96;&nbsp;P&lt;0.019). The proportion of patients alive at 24 months (87.6 percent) observed in the ERLEADA&#xAE; cohort in this real-world analysis is consistent with that in the Phase 3 TITAN trial (82.4 percent).1 TITAN demonstrated a statistically significant superior overall survival benefit of ERLEADA&#xAE; plus androgen deprivation therapy (ADT) compared to ADT alone at the primary analysis after a median 22.7 months of follow-up (HR 0.67; 95% CI, 0.51-0.89;&nbsp;P=0.005) and at the final analysis after a median 44 months of follow-up (HR 0.65; 95% CI, 0.53-0.79;&nbsp;P&lt;0.0001).1,2

Johnson & Johnson Presents Results From Study Showing That ERLEADA Demonstrates Statistically Significant And Clinically Meaningful Improvement In Overall Survival Compared To Enzalutamide In Patients With Metastatic Castration-sensitive Prostate Cancer

Johnson & Johnson To Invest More Than $2B In New, Advanced Technology Manufacturing Facility In North Carolina To Support Robust Portfolio Growth

Results from CEPHEUS study highlight DARZALEX FASPRO&#xAE; quadruplet regimen as a potential standard of care in newly diagnosed patients regardless of transplant eligibility
New indication would be the first FDA-approved treatment regimen for newly diagnosed multiple myeloma based on a study with MRD-negativity as the primary endpoint
RARITAN, N.J., Sept. 30, 2024 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for DARZALEX&nbsp;FASPRO&#xAE; (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) for whom autologous stem cell transplant (ASCT) is deferred or who are ineligible for ASCT. &nbsp;

Johnson & Johnson Files For U.S. FDA Approval Of Darzalex Faspro-Based Quadruplet Regimen For Newly Diagnosed Multiple Myeloma Patients For Whom Transplant Is Not Planned

Friday, Legend Biotech Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)&nbsp;announced late-breaking three-year follow-up data from the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41075653/carvykti-is-the-first-and-only-cell-therapy-to-significantly-extend-overall-survival-compared-to-s" rel="noreferrer noopener">Phase 3 CARTITUDE-4 study.</a>
Data shows that a single infusion of Carvykti&nbsp;(ciltacabtagene autoleucel) significantly extended overall survival (OS) for relapsed or lenalidomide-refractory multiple myeloma patients who have received at least one <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41075653/carvykti-is-the-first-and-only-cell-therapy-to-significantly-extend-overall-survival-compared-to-s" rel="noreferrer noopener">prior line of therapy</a>.
The company says Carvykti&nbsp;is now the first and only cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as the second line.
These results were presented at the 2024 International Myeloma Society Annual Meeting.
The Phase 3 CARTITUDE-4 study evaluated Carvykti&nbsp;compared to standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone&nbsp;(DPd) for relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy.
<ul>
<li>At a median follow-up of almost three years (34 months), median OS was not reached for patients in the Carvykti&nbsp;arm.</li>
<li>At 30-month follow-up, OS rates were 76% in the Carvykti&nbsp;arm and 64% for patients treated with standard therapies.&nbsp;</li>
</ul>
In patients randomized to the Carvykti arm, Carvykti reduced the risk of death by 45% compared to standard therapies, demonstrating clinically meaningful responses for patients as early as after the first relapse.
<ul>
<li>Median progression-free survival (PFS) was not reached in the Carvykti arm and 11.79 months in patients treated with standard therapies, demonstrating sustained deep and durable responses.</li>
<li>Patients in the Carvykti&nbsp;arm had a 77% complete response or better and an 85% overall response rate.</li>
<li>Patients in the Carvykti&nbsp;arm had 62% minimal residual disease (MRD)negativity at 10-5&nbsp;and 57% MRD negativity at 10-6, compared to patients treated with standard therapies (18.5%, 9%), respectively.</li>
<li>The Median duration of response was not reached in the Carvykti&nbsp;arm, but it was 18.69 months for patients treated with standard therapies.</li>
<li>Median time to symptom worsening was not reached with Carvykti&nbsp;and 34.33 months with patients treated with standard therapies.</li>
</ul>
William Blair views this data as a positive step for the company, reinforcing the case for Carvykti&#8217;s use in second-line treatment.
The analyst writes that the near-term revenue and stock performance will largely depend on the availability of commercial manufacturing slots. William Blair&#8217;s outlook remains that Legend&#8217;s valuation fairly reflects the approval of Carvykti in second-line-plus treatment, its anticipated peak revenue, and the current progress of its other pipeline programs.
Price Action: LEGN stock is up 2.29% at $50.40 during the premarket session at last check Monday.
Illustration of Phrama lab worker created with MidJourney
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41091774/prime-medicine-inks-cell-therapy-pact-with-bristol-myers-squibb-worth-over-3-5b-streamlines-pipel" target="_blank" rel="noreferrer noopener">Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline</a>.</li>
</ul>

Analyst Color

Analyst Ratings

Movers

LEGN

Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients

Cantor Fitzgerald analyst Louise Chen reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Overweight and maintains $215 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target

Johnson & Johnson Launches TECNIS Odyssey Intraocular Lens In U.S., Offering Cataract Patients Precise Vision At All Distances And Improved Contrast In Low Light, With 93% Achieving Glasses-Free Vision

45 percent reduction in risk of death achieved with CARVYKTI&reg; after three-year follow-up in landmark CARTITUDE-4 study&nbsp;
Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting
RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today long-term results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI&reg; (ciltacabtagene autoleucel)&nbsp;significantly extended overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), reducing the risk of death by 45 percent versus standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).1 With these data, CARVYKTI&reg; is now the first and only cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as second line.1&nbsp;Findings were featured as a late-breaking oral presentation at the 2024 International Myeloma Society (IMS) Annual Meeting (Abstract #OA-65).1

Johnson & Johnson And  Legend Biotech Corp Announce CARVYKTI Is The First And Only Cell Therapy To Significantly Extend Overall Survival Versus Standard Therapies For Patients With Multiple Myeloma As Early As Second Line; 45% Reduction In Risk Of Death Achieved With CARVYKTI After Three-year Follow-up In Landmark CARTITUDE-4 Study

On Friday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) released updated results from the investigational Phase&nbsp;1b&nbsp;RedirecTT-1 study evaluating the combination of Talvey&nbsp;(talquetamab) and Tecvayli&nbsp;(teclistamab) in patients with relapsed or <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n41065095/novel-combination-of-talvey-talquetamab-tgvs-and-tecvayli-teclistamab-cqyv-suggests-high-response-" rel="noreferrer noopener">refractory multiple myeloma</a>.
At data cutoff, 44 patients had been treated with the recommended phase 2 regimen (RP2R) of 0.8 mg/kg of Talvey in combination with 3 mg/kg of Tecvayli every other week.
The overall response rate (ORR) was 79.5%, with a complete response or better (CR+) rate of 52.3%, an 18-month duration of response (DOR) of 85.9%, and an 18-month progression-free survival (PFS) rate of 69.8% with a median follow-up of 18.2 months.
Results from a subgroup analysis of patients with extramedullary disease demonstrated an ORR of 61.1%, with a CR+ rate of 33.3%, an 18-month DOR of 81.8%, and an 18-month PFS rate of 52.9% in patients with EMD at median follow-up 13.6 months.
Johnson &amp; Johnson&nbsp;also revealed updated results from the investigational Phase&nbsp;1b&nbsp;TRIMM-2 study evaluating the combination of Talvey with Darzalex&nbsp;Faspro and pomalidomide in patients with relapsed or refractory multiple myeloma that demonstrated <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n41064961/talvey-talquetamab-tgvs-and-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-combination-s" rel="noreferrer noopener">an ORR of 82%</a>.
At data cutoff, 77 patients had received Talvey&nbsp;in doses of 0.4 mg/kg weekly (QW) or 0.8 mg/kg biweekly (Q2W),&nbsp;with step-up doses&nbsp;combined with Darzalex&nbsp;Faspro and pomalidomide.
In the QW arm (n=18), the overall response rate (ORR) was 100%, with 56 percent having a complete response (CR) or better.
The Q2W arm (n=59) achieved 76% ORR, with 56% achieving CR or better.
The median duration of response (DOR) in the Q2W arm was 26.4 months, and the median progression-free survival (PFS) was 20.3 months.
Results showed that 52% of anti-CD38 refractory patients (n=64) achieved CR or better, and 70.8% received prior chimeric antigen receptor T cell therapy (n=24) achieved CR or better.
Patients who had received prior bispecific antibodies (n=29) achieved an 82.8% ORR.
Price Action: JNJ stock is trading 0.83% higher at $162.73 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41066968/microsoft-google-meta-pave-path-to-ai-expansion-nvidia-and-broadcom-set-to-reap-benefits" target="_blank" rel="noreferrer noopener">Microsoft, Google, Meta Pave Path to AI Expansion, Nvidia and Broadcom Set to Reap Benefits</a>.</li>
</ul>
Photo via Shutterstock

Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment

Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to TALVEY&#xAE; and TECVAYLI&#xAE; monotherapies
RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced updated results from the investigational Phase 1b RedirecTT-1 study evaluating the first-ever bispecific antibody combination of TALVEY&#xAE; (talquetamab-tgvs), the first and only FDA-approved bispecific targeting GPRC5D, and TECVAYLI&#xAE; (teclistamab-cqyv), the first FDA-approved BCMA-directed bispecific therapy, showing high response rates and durable responses, with a consistent safety profile to each monotherapy, in patients with relapsed or refractory multiple myeloma (RRMM) who were triple-class exposed, including those with extramedullary disease. These data were featured in an oral presentation at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4264836-1&amp;h=917760301&amp;u=https%3A%2F%2Fevents.jspargo.com%2Fims24%2FPublic%2FEnter.aspx&amp;a=2024+International+Myeloma+Society+Annual+Meeting">2024 International Myeloma Society Annual Meeting</a>&nbsp;(Abstract # OA – 03).

Johnson & Johnson Announced Updated Results From The Investigational Phase 1b RedirecTT-1 Study Evaluating The First-ever Bispecific Antibody Combination Of  TALVEY And TECVAYLI Suggests High Response Rates And Durable Responses In Triple-Class Refractory Patients With Relapsed Or Refractory Multiple Myeloma, Including Those With Extramedullary Disease

Updated data show 100 percent overall response rate with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific antibody
Safety profile, including infection rates, similar to TALVEY&#xAE; and DARZALEX FASPRO&#xAE; monotherapies
RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced updated results from the investigational Phase 1b TRIMM-2 study evaluating the combination of TALVEY&#xAE; (talquetamab-tgvs) with DARZALEX FASPRO&#xAE;&nbsp;(daratumumab and hyaluronidase-fihj) and pomalidomide in patients with relapsed or refractory multiple myeloma that demonstrated an overall response rate (ORR) of 82 percent, further supporting the investigation of this combination. These data were featured in an oral presentation at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4264815-1&amp;h=1131024819&amp;u=https%3A%2F%2Fevents.jspargo.com%2Fims24%2FPublic%2FEnter.aspx&amp;a=2024+International+Myeloma+Society+Annual+Meeting">2024 International Myeloma Society Annual Meeting</a>&nbsp;(Abstract #OA – 01).
The results from the Phase 1b TRIMM-2 study evaluating TALVEY&#xAE;, the first bispecific T-cell engager to target GPRC5D, combined with DARZALEX FASPRO&#xAE;, the first subcutaneous anti-CD38 monoclonal antibody, and pomalidomide included patients who received at least three prior lines of therapy, including a proteasome inhibitor (PI) and immunomodulatory drug (IMiD), or were double refractory to a PI and IMiD and had not received anti-CD38 therapy in the previous 90 days.1&nbsp;
At data cutoff, 77 patients had received TALVEY&#xAE; in doses of 0.4 mg/kg weekly (QW) or 0.8 mg/kg biweekly (Q2W),&nbsp;with step-up doses,&nbsp;combined with DARZALEX FASPRO&#xAE; and pomalidomide. In the QW arm (n=18), the overall response rate (ORR) was 100 percent, with 56 percent having a complete response (CR) or better. The Q2W arm (n=59) achieved 76 percent ORR, with 56 percent achieving CR or better. The median duration of response (DOR) in the Q2W arm was 26.4 months, and the median progression-free survival (PFS) was 20.3 months. Results showed 52 percent of patients who are anti-CD38 refractory (n=64) achieved CR or better and 70.8 percent of patients who received prior chimeric antigen receptor T cell (CAR-T) therapy (n=24) achieved CR or better. Patients who had received prior bispecific antibodies (n=29) achieved an 82.8 percent ORR.1&nbsp;

Johnson & Johnson Announces Updated Results From The Investigational Phase 1b Trimm-2 Study Evaluating The Combination Of TALVEY And DARZALEX FASPRO Based Combination Shows Deep And Durable Responses In Patients With Relapsed Or Refractory Multiple Myeloma

In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undertake an in-depth industry comparison, assessing Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) alongside its primary competitors in the Pharmaceuticals industry. By meticulously examining crucial financial indicators, market positioning, and growth potential, we aim to provide valuable insights to investors and shed light on company's performance within the industry.
<h3>Johnson &amp; Johnson Background</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johnson &amp; Johnson</td>
<td>24.30</td>
<td>5.40</td>
<td>4.56</td>
<td>6.62%</td>
<td>$7.8</td>
<td>$15.58</td>
<td>4.31%</td>
</tr>
<tr>
<td>Eli Lilly and Co</td>
<td>113.86</td>
<td>61.38</td>
<td>21.47</td>
<td>22.5%</td>
<td>$4.12</td>
<td>$9.13</td>
<td>35.98%</td>
</tr>
<tr>
<td>Novo Nordisk AS</td>
<td>42.44</td>
<td>33.71</td>
<td>14.79</td>
<td>18.97%</td>
<td>$35.74</td>
<td>$57.79</td>
<td>25.34%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc</td>
<td>21.25</td>
<td>6.67</td>
<td>4.68</td>
<td>13.0%</td>
<td>$7.45</td>
<td>$12.37</td>
<td>7.16%</td>
</tr>
<tr>
<td>AstraZeneca PLC</td>
<td>37.64</td>
<td>6.08</td>
<td>4.93</td>
<td>5.01%</td>
<td>$4.12</td>
<td>$10.76</td>
<td>13.33%</td>
</tr>
<tr>
<td>Novartis AG</td>
<td>23.81</td>
<td>5.65</td>
<td>4.92</td>
<td>7.97%</td>
<td>$5.25</td>
<td>$9.7</td>
<td>9.6%</td>
</tr>
<tr>
<td>Sanofi SA</td>
<td>30.35</td>
<td>1.76</td>
<td>2.70</td>
<td>1.53%</td>
<td>$2.03</td>
<td>$7.97</td>
<td>6.53%</td>
</tr>
<tr>
<td>Zoetis Inc</td>
<td>37.55</td>
<td>17.47</td>
<td>9.86</td>
<td>12.45%</td>
<td>$0.97</td>
<td>$1.69</td>
<td>8.3%</td>
</tr>
<tr>
<td>GSK PLC</td>
<td>13.46</td>
<td>4.31</td>
<td>1.75</td>
<td>8.32%</td>
<td>$2.31</td>
<td>$5.76</td>
<td>9.84%</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Co Ltd</td>
<td>44.56</td>
<td>0.85</td>
<td>1.51</td>
<td>1.26%</td>
<td>$388.51</td>
<td>$821.04</td>
<td>14.11%</td>
</tr>
<tr>
<td>Dr Reddy's Laboratories Ltd</td>
<td>19.94</td>
<td>3.76</td>
<td>3.84</td>
<td>4.84%</td>
<td>$21.72</td>
<td>$46.34</td>
<td>13.87%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals PLC</td>
<td>18.28</td>
<td>1.77</td>
<td>1.93</td>
<td>4.52%</td>
<td>$0.36</td>
<td>$0.91</td>
<td>6.95%</td>
</tr>
<tr>
<td>Organon &amp; Co</td>
<td>4.90</td>
<td>34.03</td>
<td>0.77</td>
<td>203.12%</td>
<td>$0.43</td>
<td>$0.94</td>
<td>-0.06%</td>
</tr>
<tr>
<td>Corcept Therapeutics Inc</td>
<td>37.65</td>
<td>7.46</td>
<td>8.27</td>
<td>6.14%</td>
<td>$0.04</td>
<td>$0.16</td>
<td>39.15%</td>
</tr>
<tr>
<td>Prestige Consumer Healthcare Inc</td>
<td>17.31</td>
<td>2.09</td>
<td>3.19</td>
<td>2.94%</td>
<td>$0.08</td>
<td>$0.15</td>
<td>-4.36%</td>
</tr>
<tr>
<td>Average</td>
<td>33.07</td>
<td>13.36</td>
<td>6.04</td>
<td>22.33%</td>
<td>$33.8</td>
<td>$70.34</td>
<td>13.27%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>Upon a comprehensive analysis of Johnson &amp; Johnson, the following trends can be discerned: 
<ul>
<li>
With a Price to Earnings ratio of 24.3, which is 0.73x less than the industry average, the stock shows potential for growth at a reasonable price, making it an interesting consideration for market participants.
</li>
<li>
With a Price to Book ratio of 5.4, significantly falling below the industry average by 0.4x, it suggests undervaluation and the possibility of untapped growth prospects.
</li>
<li>
The Price to Sales ratio is 4.56, which is 0.75x the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
With a Return on Equity (ROE) of 6.62% that is 15.71% below the industry average, it appears that the company exhibits potential inefficiency in utilizing equity to generate profits.
</li>
<li>
The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $7.8 Billion is 0.23x below the industry average, suggesting potential lower profitability or financial challenges.
</li>
<li>
The gross profit of $15.58 Billion is 0.22x below that of its industry, suggesting potential lower revenue after accounting for production costs.
</li>
<li>
The company's revenue growth of 4.31% is significantly lower compared to the industry average of 13.27%. This indicates a potential fall in the company's sales performance.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727362846_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio provides insights into the proportion of debt a company has in relation to its equity and asset value.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When evaluating Johnson &amp; Johnson alongside its top 4 peers in terms of the Debt-to-Equity ratio, the following insights arise:
<ul>
<li>
Johnson &amp; Johnson has a stronger financial position compared to its top 4 peers, as evidenced by its lower debt-to-equity ratio of 0.58.
</li>
<li>
This suggests that the company has a more favorable balance between debt and equity, which can be perceived as a positive indicator by investors.
</li>
</ul>
<h3>Key Takeaways</h3>
For Johnson &amp; Johnson in the Pharmaceuticals industry, the PE, PB, and PS ratios are all low compared to its peers, indicating potential undervaluation. However, the low ROE, EBITDA, gross profit, and revenue growth suggest underperformance relative to industry standards. This may require further investigation into the company's operational efficiency and growth strategies to align with industry peers.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Analysis: Johnson &amp; Johnson Versus Competitors In Pharmaceuticals Industry

In October 2023, Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced its plans to spin off its consumer healthcare business as the French pharmaceutical company outlined its strategic update to increase investment in its drug-development <a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35458838/sanofi-goes-the-rival-way-plans-separation-of-consumer-healthcare-unit" rel="noreferrer noopener">pipeline and cut costs</a>.
Sanofi said the spinoff would allow it to increase its focus on innovative medicines and vaccines.
Sanofi&#8217;s consumer health unit boasts a portfolio that includes popular over-the-counter products like Phytoxil cough syrups, Icy Hot pain relief gels, and Dulcolax laxative tablets.&nbsp;
According to a Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-09-24/sanofi-said-to-get-binding-bids-from-cd-r-pai-for-consumer-arm?srnd=prognosis&amp;embedded-checkout=true" rel="noreferrer noopener">report</a>, two private equity firms, Clayton Dubilier &amp; Rice and PAI Partners, made separate bids for Sanofi&#8217;s consumer health division.
The update pushes the European pharma giant closer to one of the largest European deals this year, which could value the unit at 15 billion euros ($16.8 billion) or more, the Bloomberg report added.
The separation is expected to occur by Q4 2024 by creating a publicly listed entity headquartered in France.
In July, Goldman Sachs Group Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) and&nbsp;Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) said they were preparing to arrange more than $6.5 billion (6 billion euros) in debt financing for potential buyers interested in acquiring&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39755459/sanofis-20b-consumer-health-unit-sale-goldman-sachs-morgan-stanley-line-up-6-5b-financing" rel="noreferrer noopener">Sanofi&#8217;s&nbsp;consumer health division</a>.
The move highlighted banks&#8217; interest in supporting leveraged buyouts through pre-arranged financing.
Sanofi may opt for a spinoff of its consumer health business if the offers aren&#8217;t appealing, Bloomberg noted, citing sources. A company spokesperson told Bloomberg that Sanofi is evaluating potential separation options, with the earliest possible transaction happening in the fourth quarter of this year, and noted that preparations are progressing as planned.
In November 2023, Sanofi reportedly initiated talks with Rothschild &amp; Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business <a target="_blank" href="https://www.benzinga.com/markets/equities/23/11/35823034/major-buyout-firms-eye-sanofis-consumer-health-division-spinoff-valued-over-20b" rel="noreferrer noopener">at over $20 billion</a>.&nbsp;
Rival pharma giants&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)&nbsp;and&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) split their consumer healthcare units&nbsp;Haleon Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) and Kenvue Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>), respectively.
Price Action: SNY stock closed at $57.62&nbsp;on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/09/41012667/healthcare-software-giant-epic-systems-hit-with-lawsuit-over-alleged-monopolistic-practices" target="_blank" rel="noreferrer noopener">Healthcare Software Giant Epic Systems Hit With Lawsuit Over Alleged Monopolistic Practices</a>.</li>
</ul>
Photo via Company

Rumors

Media

KVUE

Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff

Johnson &amp; Johnson&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>), via its subsidiary called Red River Talc, for the third time, filed for voluntary bankruptcy to resolve thousands of lawsuits related to its talc products. Red River Talc has filed for Chapter 11 bankruptcy to equitably resolve all of JNJ&#39;s present and future talc-related claims in a bankruptcy court in the Southern District of Texas.
JNJ faces more than 62,000 lawsuits for its talc-based products, primarily its baby powders. The lawsuits allege that its talc products contain asbestos, which caused many women to develop ovarian cancer. JNJ insists that talc-based products are safe and do not cause cancer. JNJ has permanently discontinued the sale of its talc-based Johnson&#39;s Baby Powder.
So far this year, JNJ&#39;s shares have risen 4.7% compared with the&nbsp;industry&#39;s 23.5% increase.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/52/78741.jpg?v=633076405" />
Image Source: Zacks Investment Research
<h2>JNJ&#39;s Two Failed Bankruptcy Attempts</h2>
Johnson &amp; Johnson&#39;s subsidiary, LTL Management, which was established to manage claims in the cosmetic talc litigation, filed for voluntary bankruptcy twice in New Jersey. However, both the bankruptcy filings were rejected by courts stating that J&amp;J was not in enough financial stress to qualify for bankruptcy.
<h2>JNJ&#39;s New Plan and 3rd Bankruptcy Filing</h2>
In May 2024, LTL Management proposed a new plan committing to pay claimants a present value of approximately $6.5 billion to be paid over 25 years, which could resolve 99.75% of all pending talc lawsuits against the company.
J&amp;J said that Red River filed the bankruptcy case after it received support from around 83% of current claimants for the proposed bankruptcy plan. This&nbsp;exceeds the 75% approval threshold required by the U.S. Bankruptcy Code to secure confirmation of the proposed plan. Red River also increased its settlement commitment by $1.75 billion to approximately $8 billion.
<h2>Several Rulings Against JNJ in Talc Lawsuits</h2>
Several juries have ruled against Johnson &amp; Johnson in talc lawsuits over the years. In one such ruling, in 2018, JNJ was ordered by a Missouri court to pay $4.7 billion in damages to 22 women who made such allegations, affirming a St. Louis court jury&#39;s verdict given earlier. Though the verdict was reduced to $2.1 billion by an appeals court in June 2020, it still rejected J&amp;J&#39;s appeal to overturn the 2018 jury verdict. JJohnson &amp; Johnson paid the award, which, including interest, totaled approximately $2.5 billion. In April 2023, J&amp;J offered to pay $8.9 billion over a period of 25 years to completely resolve its cosmetic talc litigation.
JNJ believes that resolving the claims via the civil law system would take years and incur significant costs for the company. The talc lawsuits have also hurt the company&#39;s goodwill and reputation. It believes that resolving the litigation through this proposed reorganization plan would be more efficient and would compensate claimants on time. &nbsp;However, some attorneys of the claimants feel Johnson &amp; Johnson is manipulating the bankruptcy process so that it can delay jury trials and also underpay the claimants. However, the higher settlement offer and a high percentage of claimant support may improve JNJ&#39;s chances of success after the previous two failures.
<h2>JNJ&#39;s Zacks Rank and Stocks to Consider</h2>
J&amp;J currently has a Zacks Rank #3 (Hold).
<div class="chart_embed">
<h3>Johnson &amp; Johnson Stock Price and Consensus</h3>
<img alt="Johnson &amp; Johnson Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/93/1727080281.png" style="height:265px; width:591px" title="" />
Johnson &amp; Johnson price-consensus-chart | Johnson &amp; Johnson Quote
Some better-ranked drug/biotech companies are Eli Lilly (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>), Pfizer&nbsp;and Bayer (OTC: <a class="ticker" href="https://www.benzinga.com/stock/bayry#OTC">BAYRY</a>). While Lilly sports a Zacks Rank #1 (Strong Buy), Pfizer and Bayer have a Zacks Rank #2 (Buy) each.
The Zacks Consensus Estimate for Lilly&#39;s 2024 earnings has risen from $13.78 to $16.49 per share over the past 60 days. For 2025, earnings estimates have risen from $19.44 to $23.97 per share over the same timeframe. Year to date, Lilly&#39;s stock has risen 58.1%.
</div>
Lilly beat estimates in each of the last four quarters, delivering a four-quarter average earnings surprise of 69.07%.
The Zacks Consensus Estimate for Pfizer&#39;s 2024 earnings has risen from $2.38 to $2.62 per share in the past 60 days, while that for 2025 has risen from $2.74 per share to $2.85 per share. Pfizer&#39;s shares have risen 2.2% year to date.
Pfizer beat estimates in each of the last four quarters, delivering a four-quarter average earnings surprise of 69.82%.
Estimates for Bayer&#39;s 2024 earnings have risen from $1.35 to $1.38 per share over the past 60 days. For 2025, earnings estimates have risen from $1.42 to $1.44 per share over the same timeframe. Year to date, Bayer&#39;s stock has declined 13.4%.
<a href="https://www.zacks.com/stock/news/2340100/johnson-johnson-files-for-bankruptcy-over-talc-lawsuits-for-the-third-time?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2340100">To read this article on Zacks.com click here.</a>

Earnings Beats

Management

BAYRY

Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$32.50</td>
<td>$70.5K</td>
<td>38.1K</td>
<td>2.5K</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/04/24</td>
<td>$51.00</td>
<td>$32.5K</td>
<td>829</td>
<td>797</td>
</tr>
<tr>
<td>BNTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$120.00</td>
<td>$34.5K</td>
<td>1.3K</td>
<td>625</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$355.00</td>
<td>$71.7K</td>
<td>16</td>
<td>505</td>
</tr>
<tr>
<td>TGTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$40.00</td>
<td>$137.7K</td>
<td>2</td>
<td>383</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$175.00</td>
<td>$45.4K</td>
<td>513</td>
<td>382</td>
</tr>
<tr>
<td>BHVN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$45.00</td>
<td>$48.4K</td>
<td>74</td>
<td>365</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$60.00</td>
<td>$189.7K</td>
<td>4.5K</td>
<td>172</td>
</tr>
<tr>
<td>GMED</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$70.00</td>
<td>$31.6K</td>
<td>7</td>
<td>122</td>
</tr>
<tr>
<td>MNKD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$3.50</td>
<td>$30.0K</td>
<td>121</td>
<td>100</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option sweep that happens to be bullish, expiring in 116 day(s) on January 17, 2025. This event was a transfer of 1500 contract(s) at a $32.50 strike. This particular call needed to be split into 47 different trades to become filled. The total cost received by the writing party (or parties) was $70.5K, with a price of $47.0 per contract. There were 38163 open contracts at this strike prior to today, and today 2583 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option sweep with bearish sentiment. It expires in 11 day(s) on October 4, 2024. Parties traded 500 contract(s) at a $51.00 strike. This particular call needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $32.5K, with a price of $65.0 per contract. There were 829 open contracts at this strike prior to today, and today 797 contract(s) were bought and sold. 
• Regarding BNTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), we observe a call option sweep with bullish sentiment. It expires in 25 day(s) on October 18, 2024. Parties traded 150 contract(s) at a $120.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $34.5K, with a price of $230.0 per contract. There were 1345 open contracts at this strike prior to today, and today 625 contract(s) were bought and sold. 
• Regarding CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we observe a put option sweep with bullish sentiment. It expires in 4 day(s) on September 27, 2024. Parties traded 239 contract(s) at a $355.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $71.7K, with a price of $300.0 per contract. There were 16 open contracts at this strike prior to today, and today 505 contract(s) were bought and sold. 
• For TGTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), we notice a put option sweep that happens to be bearish, expiring in 116 day(s) on January 17, 2025. This event was a transfer of 82 contract(s) at a $40.00 strike. This particular put needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $137.7K, with a price of $1680.0 per contract. There were 2 open contracts at this strike prior to today, and today 383 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option sweep that happens to be bearish, expiring in 88 day(s) on December 20, 2024. This event was a transfer of 329 contract(s) at a $175.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $45.4K, with a price of $138.0 per contract. There were 513 open contracts at this strike prior to today, and today 382 contract(s) were bought and sold. 
• For BHVN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>), we notice a put option trade that happens to be bearish, expiring in 25 day(s) on October 18, 2024. This event was a transfer of 149 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $48.4K, with a price of $325.0 per contract. There were 74 open contracts at this strike prior to today, and today 365 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a call option trade with neutral sentiment. It expires in 53 day(s) on November 15, 2024. Parties traded 150 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $189.7K, with a price of $1265.0 per contract. There were 4588 open contracts at this strike prior to today, and today 172 contract(s) were bought and sold. 
• For GMED (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>), we notice a put option sweep that happens to be bearish, expiring in 88 day(s) on December 20, 2024. This event was a transfer of 102 contract(s) at a $70.00 strike. This particular put needed to be split into 31 different trades to become filled. The total cost received by the writing party (or parties) was $31.6K, with a price of $310.0 per contract. There were 7 open contracts at this strike prior to today, and today 122 contract(s) were bought and sold. 
• For MNKD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>), we notice a call option sweep that happens to be bullish, expiring in 53 day(s) on November 15, 2024. This event was a transfer of 100 contract(s) at a $3.50 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $300.0 per contract. There were 121 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BHVN

BNTX

GMED

MNKD

TGTX

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

U.S. tweaks 2025 Medicare price negotiation process

Wells Fargo's 'Core' stocks: GOOGL, HD, KO, and more

Companies that are set to benefit from lower interest rates, doesn't necessarily mean those are all the companies that will outperform all others, it's just who really stands to gain here.

3 Industries Set To Explode When Interest Rates Drop

The healthcare industry is set for growth due to the growing demand for quality healthcare services and ongoing advancements in medical technology. Hence, investors might consider investing in healthcare stocks, Johnson & Johnson (JNJ), AbbVie (ABBV), and Thermo Fisher Scientific (TMO) for safe and steady growth. Read more… Healthcare services are necessities, not luxuries, meaning demand is consistent regardless of economic conditions. People need medical care, pharmaceuticals, and health-related services regardless of the economic climate, making it a recession-resistant sector.
Given this backdrop, it could be wise to consider investing in fundamentally strong healthcare stocks, Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>), AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>), and Thermo Fisher Scientific Inc. (<a href="https://stocknews.com/stock/TMO/">TMO</a>).
The demand for healthcare services and products is growing, driven by factors like a global aging population, escalating healthcare expenses, and ongoing advancements in medical technology. Therefore, <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">global pharmaceuticals market revenue</a> is anticipated to increase at a CAGR of 4.7%, reaching $1.45 trillion by 2029.
The <a href="https://www.biospace.com/u-s-pharmaceutical-market-size-to-reach-usd-1-093-79-billion-by-2033">United States leads the world</a> in per capita prescription drug spending, accounting for 30-40% of the global market and 45% of global pharmaceutical sales, with 22% of global production. As a result, companies producing or providing these specialized drug solutions are experiencing consistent growth.
Diagnostics also plays a crucial role, which is why the global clinical diagnostics market size is worth $86.72 billion in 2024 and is projected to reach around $140.53 billion by 2033, <a href="https://www.biospace.com/clinical-diagnostics-market-size-to-hit-usd-140-53-billion-by-2033">expanding at a CAGR of 5.5%</a> between the two periods.
Given these favorable industry trends, let's look at the fundamentals of three healthcare stocks.
Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>)
JNJ is engaged in researching, developing, manufacturing, and selling healthcare products primarily focused on human health and well-being. The company offers a diversified range of products through the Innovative Medicine and MedTech segments.
On September 30, 2024, JNJ announced it had expanded the roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC - IOL), TECNIS Odyssey, in the United States. The new full visual range IOL&#x2A;1 offers patients an unmatched continuous full range of vision, so they can see clearly from far to near and between, minimizing their need for glasses.
On August 20, JNJ announced its acquisition of V-Wave Ltd., a privately held company specializing in innovative heart failure treatment. The deal includes an upfront payment of $60 million, with the potential for additional payments of up to $1.1 billion. This acquisition is set to enhance JNJ MedTech's position in the cardiovascular space, broadening its portfolio of advanced heart failure treatment options.
For the second quarter of 2024, which ended on June 30, JNJ's sales to customers increased 4.3% year-over-year to $22.45 billion. Its <a href="https://www.investopedia.com/terms/g/grossprofit.asp#:~:text=Gross%20profit%2C%20or%20gross%20income,fluctuate%20compared%20to%20production%20output.">gross profit</a> rose 3.5% from the year-ago value to $15.58 billion.
The company's adjusted net earnings from continuing operations amounted to $6.84 billion, representing a marginal increase from the same period last year. Also, its adjusted net earnings per share from continuing operations for the quarter increased 10.2% year-over-year to $2.82.
As per the updated guidance for the fiscal year 2024, JNJ forecasts operational sales between $89.20 billion and $89.60 billion, a 6% increase from 2023, primarily driven by recent acquisitions. The company also expects adjusted EPS between $9.97 and $10.07.
The consensus revenue estimate of $22.47 billion for the fiscal fourth quarter (ending December 2024) represents a 5% increase year-over-year. The company expects its EPS to be $2.28. The company has an impressive earnings surprise history; it surpassed the consensus EPS estimates in each of the trailing four quarters.
Over the past three months, the stock has surged 10.1%, closing the last trading session at $161.17.
JNJ's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its promising outlook. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
JNJ has a B grade for Value, Stability, and Quality. It is ranked #17 out of 159 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/JNJ/">Click here</a> to see the additional ratings for JNJ (Growth, Momentum, and Sentiment).
AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>)
ABBV is a global diversified research-based biopharmaceutical company engaged in manufacturing and selling medications and therapies. It offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties.
On August 19, ABBV received conditional marketing authorization from the EC for TEPKINLY (epicoritamab). This approval marks the first and only subcutaneous bispecific antibody granted such status as a monotherapy for treating both relapsed or refactory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL) after two or more prior therapies.
In the same month, ABBV announced the acquisition of Cerevel Therapeutics (<a href="https://stocknews.com/stock/CERE/">CERE</a>) to strengthen its position in neuroscience and expand its portfolio in psychiatry, migraine, and Parkinson's disease, bolstering its existing pipeline and market presence.
For the six-month period that ended on June 30, 2024, ABBV's net revenue increased 2.6% year-over-year to $26.77 billion, while the company's Neuroscience segment reported net revenue of $4.13 billion, indicating a 15.3% growth from the prior-year period.
ABBV's attributable net income came in at $2.74 billion, up 21% year-over-year, while its earnings per share attributable grew 21.4% from the year-ago value to $1.53.
Looking ahead, ABBV raised its adjusted EPS to range between $10.71 and $10.91 from the prior forecast of $10.61 and $10.81.
Street expects ABBV's revenue and EPS for the fiscal fourth quarter (ending December 2024) to increase 2.4% and 5.7% year-over-year to $14.64 billion and $2.95, respectively. Moreover, it beat the revenue estimates in each of the trailing four quarters, which is promising.
Shares of ABBV have gained 27% over the past nine months and 32% over the past year to close the last trading session at $196.82.
ABBV's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, equating to a Strong Buy in our proprietary rating system.
ABBV has a B grade for Growth, Value, Sentiment, Stability, and Quality. It is ranked #3 out of 159 stocks in the Medical - Pharmaceuticals industry.
In addition to the POWR Ratings we've stated above, we also have ABBV ratings for Momentum. Get all ABBV ratings <a href="https://stocknews.com/stock/ABBV/">here</a>.
Thermo Fisher Scientific Inc. (<a href="https://stocknews.com/stock/TMO/">TMO</a>)
TMO is engaged in helping life sciences research, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies globally. It operates through four segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Biopharma Services.
On July 10, TMO acquired Olink Holding AB (<a href="https://stocknews.com/stock/OLK/">OLK</a>), a leading provider of next-generation proteomics solutions, in a transaction valued at approximately $3.10 billion, net of $96 million in acquired cash.
This acquisition will be integrated into TMO's Life Sciences Solutions segment. This move enhances TMO's capabilities in the rapidly growing proteomics market, accelerating scientific discoveries and boosting shareholder value.
For the second quarter of 2024, which ended on June 29, TMO's operating income increased 15.3% year-over-year to $1.82 billion. Its adjusted net income for the quarter amounted to $2.06 billion, representing an increase of 3% from the same period last year, while its adjusted EPS stood at $5.37, up 4.3% year-over-year. Also, the company's non-GAAP free cash flow grew 32.8% from the year-ago value to $1.67 billion.
Building on this quarter's momentum and successful acquisition, the company updated its annual guidance for 2024. TMO anticipates full-year revenue to range between $42.40 billion and $43.30 billion. It also forecasts adjusted EPS in the range of $21.29 to $22.07, slightly higher than the prior forecast of $21.14 to $22.02.
The consensus revenue estimate of $11.35 billion for the fiscal fourth quarter (ending December 2024) represents a 4.2% increase year-over-year. The consensus EPS estimate of $5.98 for the same quarter indicates a 5.5% improvement year-over-year. The company has an impressive earnings surprise history; it surpassed the consensus EPS estimates in each of the trailing four quarters.
Over the past nine months, the stock has surged 15.4%, closing the last trading session at $612.72.
TMO's POWR Ratings reflect its bright outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. 
TMO has a B grade for Stability and Sentiment. It is ranked #8 out of 39 stocks in the <a href="https://stocknews.com/category/medical-diagnostics-research/">Medical - Diagnostics/Research</a> industry. <a href="https://stocknews.com/stock/TMO/">Click here</a> to see the additional ratings for TMO (Growth, Value, Momentum, and Quality). 
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
JNJ shares were trading at $160.52 per share on Thursday afternoon, down $0.65 (-0.40%). Year-to-date, JNJ has gained 4.81%, versus a 20.38% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/jnj-abbv-tmo-cere-olk-3-healthcare-stocks-for-safe-steady-growth/>3 Healthcare Stocks for Safe, Steady Growth</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Stocks for Safe, Steady Growth

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on LivaNova (LIVN – Research Report), Johnson & Johns...

Analysts Conflicted on These Healthcare Names: LivaNova (LIVN), Johnson & Johnson (JNJ) and Avidity Biosciences (RNA)

In a report released today, Nico Chen from DBS maintained a Hold rating on Johnson & Johnson (JNJ – Research Report). The company's shares closed y...

DBS Remains a Hold on Johnson & Johnson (JNJ)

Stock Picks From Seeking Alpha's September 2024 New Analysts

Johnson & Johnson halts mid-stage study for dengue antiviral

Election Outcome Presents Opportunity For Investors

Buy 2 October Dogs Of The Dow And Watch 5 More

AAPL

ABBV

ACTV

AFMC

AFSM

AMGN

ARKK

AVGO

AVUV

BAPR

CERE

CMCSA

CRWD

CSCO

CUKPF

DELL

EVGGF

EVVTY

FROG

FSLR

GRAL

ICLN

INMD

IVOO

IVOV

LIVN

LSTR

MDALF

OLPX

ORCL

PAYX

PILBF

REGN

RIOCF

SBUX

SOUN

SOUNW

SPLV

SPMD

SPMO

SPMV

SPSM

SPUS

SPUU

SPVM

SPVU

SPXE

SPXL

SPXN

SPXS

SPXT

SPXU

SPXV

SPYD

SPYG

SPYV

SPYX

SQEW

SQLV

SSPY

SVAL

SYLD

TDBCP

TDBKF

TDOMF

TDOPF

TMDV

TNTTF

TPHD

TPLC

TPSC

UAUG

UJAN

UMAR

UMAY

UOCT

UPRO

USMC

USMF

USVM

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

MRNA

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Press Releases

Novel combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease

DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned

DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma

CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line

Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting

Comments

Johnson & Johnson

뉴스

에 대한 최신 뉴스 Johnson & Johnson (NYSE:JNJ) 주식

화요일, 8월 20, 2024

수요일, 7월 17, 2024

화요일, 7월 02, 2024

화요일, 4월 16, 2024

월요일, 4월 08, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌